We represented SkyKnight Capital, L.P., a private equity firm with a track record of building industry-defining businesses alongside exceptional management teams, in its definitive agreement to partner with Apex Infusion, a leading omnichannel infusion services provider. Apex’s clinician-led management team will continue to lead the business while retaining a significant ownership stake, with FFL Partners continuing as a minority investor. The partnership is subject to customary closing conditions, including the receipt of required regulatory approvals.
This transaction is highlighted in several media outlets including:
- “Apex Infusion Partners with SkyKnight Capital“– Business Wire
- “SkyKnight to invest in infusion services provider Apex Infusion” – PE Hub
- “Apex Infusion targets its next growth phase as SkyKnight Capital enters the infusion market” – Business-News-Today.com
About SkyKnight Capital
SkyKnight Capital focuses on partnering with high quality businesses in acyclical growth sectors alongside exceptional management teams. SkyKnight manages ~$6.5 billion in private equity capital on behalf of leading endowments, foundations, pensions, and institutional family offices. SkyKnight aims to build industry-defining businesses across the healthcare, financial services, and tech-enabled services industries. For more information visit www.skyknightcapital.com.
About Apex Infusion
Apex Infusion is a leading omnichannel infusion provider, delivering high-quality, patient-focused therapies across an expansive network of ambulatory infusion suites and in-home care. Founded in 2006, Apex is dedicated to expanding access to essential infusion care while delivering outcomes and creating value for patients, providers, and payors across the healthcare ecosystem. For more information visit www.apexinfusion.com/.